Clinical Trial Update: Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial is assessing ocular safety/assessments in patients with recurrent or metastatic cervical cancer treated with Tivdak (tisotumab vedotin). The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TIVDAK (tisotumab vedotin)

Snippet

Sponsor: Pfizer | Conditions: Cervical Cancer | Phase 4 | Status: RECRUITING